The race to an orally active Factor Xa inhibitor: Recent advances

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 4, 2004, Pages 460-469

  Quan, Mimi L ^a   Smallheer, Joanne M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anticoagulant; Antithrombotic; Factor Xa; Thrombosis

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BENZAMIDINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; PYRAZOLE DERIVATIVE; RAZAXABAN; SN 429; SULFONAMIDE; THROMBIN; UNCLASSIFIED DRUG; ANTITHROMBIN III;

BINDING AFFINITY; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; IC 50; IN VIVO STUDY; NONHUMAN; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG SCREENING; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBIN III; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; THROMBOEMBOLISM;

EID: 4644221541     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Hyers TM: Management of venous thromboembolism. Past, present and future. Arch Intern Med (2003) 163(7):759-768.
2. Weitz JI: Low-molecular-weight heparins. New Engl J Med (1997) 337(10):688-698.
3. Turpie AG, Antman EM: Low-molecular-weight heparins in the treatment of acute coronary syndromes. Arch Intern Med (2001) 161(12):1484-1490.
4. Samama MM, Gerotziafas GT: Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res (2003) 109(1):1-11.
5. Sorbera LA, Bayès M, Castaner J, Silvestre J: Melagatran and ximelagatran. Drugs Future (2001) 26(12):1155-1170.
6. Ruef J, Katus HA: New antithrombotic drugs on the horizon. Expert Opin Investig Drugs (2003) 12(5):781-797.
7. Leadley RJ Jr: Coagulation Factor Xa inhibition: Biological background and rationale. Curr Top Med Chem (2001) 1(2):151-159.
8. Hauptmann J, Stürzebecher J: Synthetic inhibitors of thrombin and Factor Xa: From bench to bedside. Thromb Res (1999) 93(5):203-241.
9. Mann KG, Burenas S, Brummel K: The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol (2003) 23(1):17-25.
10. Walenga JM, Jeske WP, Hoppensteadt D, Fareed J: Factor Xa inhibitors: Today and beyond. Curr Opin Investig Drugs (2003) 4(3):272-281.
11. Samama MM: Synthetic direct and indirect Factor Xa inhibitors. Thromb Res (2002) 106(3):V267-V273.
12. Kaiser B: Factor Xa - A promising target for drug development. Cell Mol Life Sci (2002) 59(2):189-192.
13. Comp PC: Selective Factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery. Pharmacotherapy (2003) 23(6):772-787.
14. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA et al: First experience with direct Factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation. Circulation (2002) 105(20):2385-2391.
15. Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ: Antithrombotic effects of DX-9065a, a direct Factor Xa inhibitor: A comparative study in humans versus low-molecular-weight heparin. Thromb Haemost (2002) 88(5):733-738.
16. Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM et al: The discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[(1,1-biphenyl)] -4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective and orally bioavailable inhibitor of blood coagulation Factor Xa. J Med Chem (2001) 44(4):566-578. Review discussing the SAR leading to the discovery of DMP-423, a potent and selective fXa inhibitor with good oral bioavailability and antithrombotic efficacy.
17. Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY, Pinto DJ, Wexler RR, Knabb RM: Nonpeptide Factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther (2002) 303(3):993-1000.
18. Wong PC, Pinto DJ, Knabb RM: Nonpeptide Factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovascular Drug Rev (2002) 20(2):137-152. Summary of the in vitro and in vivo pharmacology of DMP-423.
19. Pruitt JR, Pinto DJ, Galemmo RA Jr, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H et al: Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2′-(aminosulfonyl) -[(1,1′-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable Factor Xa inhibitor. J Med Chem (2003) 46(25):5298-5315.
20. Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ, Galemmo RA, Fevig JM, Teteha CA, Alexander RS, Smallwood AM, Rossi KA et al: Structure-based design of novel guanidine/benzamidine mimics: Potent and orally bioavailable Factor Xa inhibitors as novel anticoagulants. J Med Chem (2003) 46(21):4405-4418. A good example of rational design resulting in the discovery of novel benzamidine mimics.
21. Lam PY, Quan M, He M, Li R, Clark CG, Pinto DJP, Teleha CA, Alexander RS, Rossi KA, Wright MR, Bai SA et al: Discovery of BMS-561389/DPC 906, a highly potent, selective and orally bioavailable Factor Xa inhibitor. 226th ACS Meeting, New York, NY, USA (2003):MEDI 78.
22. Quan ML, Lam PY, Han Q, Pinto DJ, He M, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS et al: Discovery of 1-(3′-aminobenzisoxazol- 5′-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2′-dimethylaminornethyl) imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent and selective, orally bioavailable Factor Xa inhibitor. J Med Chem (2004): in press. Successful lead optimization leading to the identification of razaxaban.
23. Wong PC, Watson CA, Grain EJ, Zaspel AM, Luettgen JM, Bai SM, Lam PY, Quan ML, Wexler RR, Knabb RM: Antithrombotic effects of razaxaban, an orally-active Factor Xa inhibitor, in rabbit models of thrombosis. Blood (2003) 102(11):Abs 3011.
24. Jia ZJ, Wu Y, Huang W, Goldman E, Zhang P, Woolfrey J, Wong P, Huang B, Sinha U, Reed A, Scarborough RM et al: Design, synthesis and biological activity of novel non-amidine Factor Xa inhibitors. Part 1: P1 structure-activity relationships of the substituted 1-(2-naphthyl)-1H-pyrazolo-5-carboxylamides. Bioorg Med Chem Lett (2002) 12(12):1651-1655.
25. Jia ZJ, Wu Y, Huang W, Zhang P, Clizbe LA, Goldman EA, Sinha U, Arfsten AE, Edwards ST, Alphonso M, Hutchaleelaha A et al: 1-(2-Naphthyl)-1H-pyrazole-5- carboxylamides as potent Factor Xa inhibitors. Part 2: A survey of P4 motifs. Bioorg Med Chem Lett (2004) 14(5):1221-1227.
26. Jia ZJ, Wu Y, Huang W, Zhang P, Song Y, Woolfrey J, Sinha U, Arfsten AE, Edwards ST, Hutchaleelaha A, Hollennbach SJ et al: 1-(2-Naphthyl)-1H-pyrazole-5- carboxylamides as potent Factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors. Bioorg Med Chem Lett (2004) 14(5):1229-1234.
27. 2-Aroylanthranilamide inhibitors of human Factor Xa. J Med Chem (2000) 43(5):873-882.
28. Ye B, Cheeseman S, Chou YL, Ewing J, Fitch R, Griedel BD, Karanjawala R, Lee W, Lentz D, Liang A, Morrissey MM et al: Design, synthesis, and biological activity of novel non-amidine Factor Xa inhibitors, 4: Optimization of hydrophilic substituents for potency and oral availability. 221st ACS Meeting, San Diego, CA, USA (2001):MEDI 128.
29. Shrader WD, Young WB, Sprengeler PA, Sangalang JC, Elrod K, Carr G: Neutral inhibitors of the serine protease Factor Xa. Bioorg Med Chem Lett (2001) 11(14):1801-1804.
30. Liang AM, Light DR, Kochanny M, Rumennik G, Trinh L, Lentz D, Post J, Morser J, Snider M: Discovery and characterization of a potent and selective non-amidine inhibitor of Factor Xa. Biochem Pharmacol (2003) 65(9):1407-1418.
31. Chou YL, Davey DD, Eagen KA, Griedel BD, Karanjawala R, Phillips GB, Sacchi KL, Shaw KJ, Wu SC, Lentz D, Liang AM et al: Structure-activity relationships of substituted benzothiophene-anthranilamide Factor Xa inhibitors. Bioorg Med Chem Lett (2003) 13(3):507-511. Report on subnanomolar fXa inhibitors with neutral P1 substituents.
32. Zhang P, Bao L, Zuckett JF, Goldman EA, Jia ZJ, Arfsten A, Edwards S, Sinha U, Hutchaleelaha A, Park G, Lambing JL et al: Design, synthesis and SAR of anthranilamide-based Factor Xa inhibitors incorporating substituted biphenyl P4 motifs. Bioorg Med Chem Lett (2004) 14(4):983-987.
33. Zhang P, Bao L, Zuckett JF, Jia ZJ, Woolfrey J, Arfsten A, Edwards S, Sinha U, Hutchaleelaha A, Lambing JL, Hollenbach SJ et al: Design, synthesis, and SAR of anthranilamide-based Factor Xa inhibitors with improved functional activity. Bioorg Med Chem Lett (2004) 14(4):989-993. Disclosure of an analog with a novel 2-iminooxazolidine P4 group demonstrating good in vivo efficacy and oral bioavailability in rats.
34. Choi-Sledeski YM, Keamey R, Poli G, Pauls H, Gardner C, Gong Y, Becker M, Davis R, Spada A, Liang G, Chu V et al: Discovery of an orally efficacious inhibitor of coagulation Factor Xa which incorporates a neutral P1 ligand. J Med Chem (2003) 46(5):681-684. SAR study leading to the identification of RPR-209685, which displayed a reversal of the canonical fXa binding orientation with a neutral group in the P1 pocket and a basic group in the P4 pocket.
35. Maignan S, Guilloteau JP, Choi-Sledeski YM, Becker MR, Ewing WR, Pauls HW, Spada AP, Mikol V: Molecular structures of human Factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket. J Med Chem (2003) 46(5):685-690. Additional examples of fXa-inhibitor crystal complexes with neutral P1 groups.
36. Levell JR, Pauls HW, Choi Y-M, Ewing WR, Becker MR, McGarry DG, Gardner CJ, Poli GB, Czekaj M, Gong Y, Li A et al: Aminoquinazoline, aminoquinoline and aminoisoquinoline substituted 3(R)- and 3(S)- aminopyrrolidin-2-one derived Factor Xa inhibitors. 226th ACS Meeting, New York, NY, USA (2003):MEDI 77.
37. Huang W, Naughton MA, Yang H, Su T, Dam S, Wong PW, Arfsten A, Edwards S, Sinha U, Hollenbach S, Scarborough RM et al: Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state Factor Xa inhibitors. Bioorg Med Chem Lett (2003) 13(4):723-728.
38. Su T, Yang H, Volkots D, Woolfrey J, Dam S, Wong P, Sinha U, Scarborough RM, Zhu BY: Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state Factor Xa inhibitors. Bioorg Med Chem Lett (2003) 13(4):729-732.
39. Zhaozhong JJ, Su T, Zuckett JF, Wu Y, Goldman EA, Li W, Zhang P, Clizbe LA, Song Y, Bauer SM, Huang W et al: N,N-Dialkylated 4-(4- arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo- piperazin-1-ylmethyl)-benzamidines as potent Factor Xa inhibitors. Bioorg Med Chem Lett (2004) 14(9):2073-2078.
40. Masters JJ, Weber WW, Franciskovich JB, Wiley MR, Halligan NG, Camp NP, Jones SD, Richards S, Lyons A, Morgan P, Liebeschuetz JW et al; Bicyclic S1-binding constructs in a series of phenyl glycine-based inhibitors of human Factor Xa. 224th ACS Meeting, Boston, MA, USA (2002):MEDI 284.
41. Sheehan SM, Masters JJ, Wiley MR, Young SC, Liebeschuetz JW, Jones SD, Murray CW, Franciskovich JB, Engel DB, Weber WW, Marimuthu J et al: A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent Factor Xa inhibitors. Bioorg Med Chem Lett (2003) 13(14):2255-2259.
42. Sheehan SM, Watson BM, Wiley MR, Liebeschuetz JW, Sall DJ, Franciskovich JB, Marimuthu J, Smallwood JK, Foster RS, Froelich LL, Gifford-Moore D et al: 1,2-Aminoethanol-derived non-covalent Factor Xa inhibitors. 226th ACS Meeting, New York, NY, USA (2003):MEDI 357.
43. Sheehan SM, Watson BM, Wiley MR, Liebeschuetz JW, Sall DJ, Franciskovich JB, Marimuthu J, Smallwood JK, Patel NJ, Woodland J, Barbuch R et al: SAR investigation on the in vitro metabolism of 1,2-aminoethanol-derived non-covalent Factor Xa inhibitors. 226th ACS Meeting. New York, NY, USA (2003):MEDI 82.
44. Mederski WW, Germann M: A general synthesis of 1-aryl carbamoyl-2-alkyl-4-aryl substituted semicarbazides as nonbasic Factor Xa inhibitors. Bioorg Med Chem Lett (2003) 13(21):3715-3718.
45. Sagi K, Nakagawa T, Yamanashi M, Makino S, Takahashi M, Takayanagi M, Takenaka K, Suzuki N, Oono S, Kataoka N, Ishikawa K et al: Rational design, synthesis and structure-activity relationships of novel Factor Xa inhibitors: (2-Substituted-4-amidinophenyl)pyruvic and propionic acids. J Med Chem (2003) 46(10):1845-1857.
46. Nagahara T, Yokoyama Y, Inamura K, Katakura S, Komoriya S, Yamaguchi H, Hara T, Iwamoto M: Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation Factor Xa inhibitors. J Med Chem (1994) 37(8):1200-1207.
47. Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC: DX-9065a, a novel, synthetic, selective and orally active inhibitor of Factor Xa: In vitro and in vivo studies. J Pharmacol Exp Ther (1996) 276(3):1030-1038.
48. Komoriya S, Kanaya N, Nagahara T, Yokoyama A, Inamura K, Yokoyama Y, Katakura S, Hara T: Design, synthesis and biological activity of amindinobicyclic compounds (derivatives of DX-9065a) as Factor Xa inhibitors: SAR study of S1 and aryl binding sites. Bioorg Med Chem (2004) 12(9):2099-2114. Identification of a 6-amidino-1-ethylindole analog of DX-9065a with improved fXa potency and oral bioavailability in rats.
49. Hirayama F, Koshio H, Katayama N, Kurihara H, Taniuchi Y, Sato K, Hisamichi N, Sakai-Moritani Y, Kawasaki T, Matsumoto Y, Yanagisawa I: The discovery of YM-60828: A potent, selective and orally-bioavailable Factor Xa inhibitor. Bioorg Med Chem (2002) 10(5):1509-1523.
50. Iwatsuki Y, Kaku S, Moritani Y, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y, Mano Y, Kawasaki T: Antithrombotic effects of YM466, a synthesized direct inhibitor of Factor Xa, in an arterio-venous shunt thrombosis model in squirrel monkeys. Drug Dev Res (2003) 58(2):190-195.
51. Koshio H, Hirayama F, Ishihara T, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S: Synthesis and biological activity of novel 1,4-diazepine derivatives as Factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorg Med Chem (2004) 12(9):2179-2191. Optimization of the P4 moiety in YM-60828 provided YM-96765, which demonstrated antithrombotic efficacy in animal models and good oral bioavailability in cynomolgus monkeys.
52. Hirayama F, Koshio H, Katayama N, Ishihara T, Kaizawa H, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kurihara H, Kawasaki T et al: Design, synthesis and biological activity of YM-60828 derivatives. Part 2: Potent and orally bioavailable Factor Xa inhibitors based on benzothiadiazine-4-one template. Bioorg Med Chem (2003) 11(3):367-381. Identification of YM-169920 with improved potency and trypsin selectivity compared to YM-60828, and oral bioavailability in both mice and squirrel monkeys.
53. Brandstetter H, Kühne A, Bode W, Huber R, von der Saal W, Wirthensohn K, Engh RA: X-ray structure of active site-inhibited clotting Factor Xa. J Biol Chem (1996) 271(47):29988-29992.
54. Huang W, Zhang P, Zuckett JF, Wang L, Woolfrey J, Song Y, Jia ZJ, Clizbe LA, Su T, Tran K, Huang B et al: Design, synthesis and structure-activity relationships of benzoxazinone-based Factor Xa inhibitors. Bioorg Med Chem Lett (2003) 13(3):561-566.
55. Deng JZ, Burgey CS, Rabbat PMA, Lewis SD, Lucas, BJ, Krueger JA, White RB, Wong B, Lyle EA, McMasters DR, Lynch JJ, Yan Y, Chen Z, Kuo L, Vacca JP, Lyle TA: Benzoxazole thrombin and Factor Xa inhibitors. 227th ACS Meeting, Anaheim, CA, USA (2004):MEDI 95.
56. Shi Y, Sitkoff D, Zhang J, Grazier N, Stein PD, Atwal K, Bisacchi G, Zhang J, Liu ECK, Seiler SM, Harl KS, Schumacher WA, Youssef SA, Klie H, Pudzianowski A, Kish K, Yanchunas J: Ketene aminal-based lactam derivatives as a novel class of orally bioavailable fXa inhibitors. 226th ACS Meeting, New York, NY, USA (2003):MEDI 81.
57. Clement B: Reduction of N-hydroxylated compounds: Amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev (2002) 34(3):565-579.
58. Song Y, Clizbe L, Bhakta C, Teng W, Wong P, Huang B, Tran K, Sinha U, Park G, Reed A, Scarborough RM et al: Design and synthesis of Factor Xa inhibitors and their prodrugs. Bioorg Med Chem Lett (2003) 13(2):297-300.
59. Norman P: Medicinal Chemistry - 12th RSC-SCI Symposium (Part I), Enzyme inhibitors, Cambridge, UK. IDdb3 Meeting Report, Thomson Scientific, London, UK (2003).
60. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M: Single dose escalation study investigating the pharmacodynamics, safety and pharmacokinetics of BAY59-7939 an oral direct Factor Xa inhibitor in healthy male subjects. Blood (2003) 102(11):Abs 3010.
61. Harder S, Graff J, Hentig NV, Misselwitz F, Kubitza D, Zuelsdorf M, Wensing G, Mueck W, Becka M, Breddin HK: Effects of BAY59-7939, an oral, direct Factor Xa inhibitor, on thrombin generation in healthy volunteers. Blood (2003) 102(11):Abs 3003.
62. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M: Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY59-7939, an oral, direct Factor Xa inhibitor in healthy male subjects. Blood (2003) 102(11):Abs 3004.
63. Barrett JS, Davidson AF, Jiao QT, Mosqueda-Garcia R, Kornhauser DM, Gangrade NK, Jona JA, Pieniaszek HJ Jr: The effect of food, formulation, and dosing duration on the pharmacokinetics of DPC423, a potent Factor Xa inhibitor. J Clin Pharmacol (2001) 41:1023.
64. Swaminathan A, Frost C, Bai S, Knabb R, Komhauser D, Mosqueda-Garcia R: Pharmacokinetic and pharmacodynamic characteristics in healthy volunteers of razaxaban, an orally-active, potent, selective inhibitor of Factor Xa. Clin Pharmacol Ther (2004) 75(2):P6.
65. Zafar MU, Viles-Gonzalez J, Valdiviezo C, Anand SX, Vorchheimer D, Mosqueda-Garcia R, Fuster V, Badimon JJ: Tissue factor pathway inhibition, a new antithrombotic strategy: Phase I study of a novel, oral Factor Xa inhibitor. 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA (2004):Abs 1007-173.
66. Lassen, MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D: A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery - On behalf of the razaxaban investigators. Blood (2003) 102(11):Abs 41.